Business
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration studyHONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug Application (NDA) for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has been granted approval by the China Natio
About this update from Hutchmed (china) Limited
[{"type":"image","alt":"HUTCHMED (China) Limited","displaySize":"","headline":null,"caption":"HUTCHMED (China) Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/96f02f9f1009ccc284c00f92693f0df0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZJVE1lCMKkq0VyPhjqtrPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/96f02f9f1009ccc284c00f92693f0df0","width":300,"height":92},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZJVE1lCMKkq0VyPhjqtrPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/96f02f9f1009ccc284c00f92693f0df0","width":300,"height":92}},"lazy":false},{"type":"text","content":"Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study","length":119,"tagName":"p"},{"type":"text","content":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug Application (NDA) for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has been granted approval by the China National Medical Products Administration (“NMPA”) for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI) therapy and have not received programmed death receptor-1 (“PD-1”) or programmed death-ligand 1 (“PD-L1”) inhibitor therapy in the first-line setting.","length":768,"tagName":"p"},{"type":"text","content":"The approval is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of patients with locally advanced or metastatic renal cell carcinoma. The study met its primary endpoint of progression free survival (“PFS”) as assessed by blinded independent central review (“BICR”).","length":468,"tagName":"p"},{"type":"text","content":"“The rapid advancements in targeted therapies, immunotherapies, and their combination regimen...